Ketogenic Diet for Depression
NCT06105762 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120
Last updated 2023-10-30
Summary
Globally, it's estimated that around 300 million people are affected by depressive illness, and even with access to modern mental health care, long-term recovery is uncommon. Recently, there has been increasing interest in a promising intervention: the ketogenic diet. This diet restricts carbohydrate intake, promoting the breakdown of fats into circulating ketone bodies, which can act as an additional energy source for the brain, potentially reducing its reliance on glucose. While various sources of evidence suggest the potential benefits of the ketogenic diet for individuals with depression, robust clinical studies on its efficacy in depressed patients are lacking. Our goal is to conduct an eight-week, assessor-blinded, randomized controlled trial to investigate the therapeutic effects of a very low-carbohydrate, high-fat ketogenic diet compared to an active comparator diet in individuals with depression.
Conditions
- Depressive Disorder
- Major Depressive Disorder
- Depression, Bipolar
Interventions
- OTHER
-
Ketogenic Diet
The ketogenic diet intervention, administered as a Modified Atkins Diet, involves a significantly reduced daily carbohydrate intake, typically less than 20 grams of net carbs. This approach primarily relies on higher fat consumption to induce ketosis, a metabolic state characterized by elevated ketone body production, serving as an alternative brain fuel source.
Sponsors & Collaborators
-
University Psychiatric Clinics Basel
lead NETWORK
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-01-01
- Primary Completion
- 2027-01-01
- Completion
- 2027-07-01
More Related Trials
-
Clinical Trial of the Use of Ketamine in Treatment Resistant Depression
NCT02610712 ·Status: UNKNOWN ·Phase: PHASE4
-
Study of Depression-Ketamine-Brain Function
NCT01135758 ·Status: TERMINATED ·Phase: PHASE2
-
Cognitive Training as an Adjunct to Ketamine in Real-world Clinics
NCT06526078 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
NCT03973268 ·Status: RECRUITING ·Phase: PHASE1
-
Ketamine Treatment Effects on Synaptic Plasticity in Depression
NCT04091971 ·Status: COMPLETED ·Phase: PHASE4
-
Ketamine for Depression Relapse Prevention Following ECT
NCT02414932 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Brain Energy Metabolism in Individuals With Major Depressive Disorder Receiving Escitalopram
NCT00183677 ·Status: COMPLETED ·Phase: PHASE4
-
Ketamine for Depression: An MRI Study
NCT02544607 ·Status: COMPLETED ·Phase: PHASE4
-
Repeated Neurocognitive Measurements in Depressed Patients
NCT04916548 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Rapid Antidepressant Effects of Ketamine in Major Depression
NCT00088699 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Ketamine in the Treatment of Depression
NCT01558063 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Ketamine as an Antidepressant in Major Depressive Disorder
NCT01573741 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Physiological and Cognitive Biomarkers for Ketamine's Antidepressant Effects
NCT02669043 ·Status: TERMINATED ·Phase: NA
-
Neurotrophic Factors and Depression
NCT00812994 ·Status: COMPLETED ·Phase: PHASE4
-
Intramuscular Ketamine Versus Aripiprazole and Escitalopram in the Treatment of Resistant Depression
NCT04234776 ·Status: UNKNOWN ·Phase: PHASE4
-
Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression
NCT06480201 ·Status: SUSPENDED ·Phase: PHASE1
-
Evaluation of Schemes of Administration of Intravenous Ketamine in Depression
NCT03742557 ·Status: UNKNOWN ·Phase: PHASE3
-
Nebulized Ketamine for the Treatment of Major Depressive Disorder
NCT06752759 ·Status: RECRUITING ·Phase: PHASE3
-
Neural Circuit Effects of Ketamine in Depression
NCT06213324 ·Status: RECRUITING ·Phase: PHASE4
-
Ketamine for Treatment Resistant Late-Life Depression
NCT02556606 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Ketamine on Neurological Activity as Measured by Electroencephalogram (EEG)
NCT05095792 ·Status: TERMINATED
-
The Role of PKC Activation in the Immune-inflammatory Mechanism of Major Depressive Depression
NCT04156425 ·Status: UNKNOWN ·Phase: NA
-
In Vitro Modeling of Drug-resistant Psychiatric Disorders Using Induced Pluripotent Cells
NCT05887310 ·Status: UNKNOWN
-
Safety and Effectiveness Study of BCI-540 Versus Placebo in the Treatment of Major Depressive Disorder With Concomitant Anxiety
NCT00621270 ·Status: COMPLETED ·Phase: PHASE2
-
Action of Ketamine in Treatment-Resistant Depression
NCT01945047 ·Status: COMPLETED ·Phase: PHASE2/PHASE3